ライフサイエンスコーパス: acneiform

1 4 toxicity was rash (14% maculopapular, 8.6% acneiform).

2 placebo plus erlotinib group were dermatitis acneiform (20 [9%]) and increased alanine aminotransfera

3 mon grade 3-4 adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs

4 sion (52 [24%]; grade 3 only) and dermatitis acneiform (33 [15%]), and in the placebo plus erlotinib

5 ertension (6.4% versus 3.7%), and dermatitis acneiform (5.0% versus 0).

6 which is characterized by a large number of acneiform and papular skin lesions, with very few or no

7 toxicities (grade 2 hypertension, dermatitis acneiform, and memory impairment in patient 1, and grade

8 in other follicular pathologies, such as the acneiform conditions, are inadequately explored and must

9 g (rash) and two of five patients at 350 mg (acneiform dermatitis and fatigue/decreased Eastern Coope

10 tment-related adverse events were dermatitis acneiform, diarrhea, and nausea in adults and dermatitis

11 iarrhea, and nausea in adults and dermatitis acneiform, diarrhea, and paronychia in children.

12 most common adverse event among patients was acneiform eruption in 2 of 20 patients (10%).

13 This case series study found that acneiform eruption is an adverse event associated with E

14 The mechanism of ELX-TEZ-IVA-associated acneiform eruption is currently unknown, but the observa

15 e diarrhoea in 83 (93%) patients, dermatitis acneiform in 69 (78%) patients, dry skin in 39 (44%) pat

16 dverse event with selumetinib was dermatitis acneiform (n = 11 [7%]).

17 se-limiting toxicities, including dermatitis acneiform (n = 2), maculopapular rash (n = 2), increased

18 lated adverse events were rash or dermatitis acneiform (n=165; 80%) and diarrhoea (87; 42%), most of

19 lated adverse events were rash or dermatitis acneiform (n=80; 82%) and diarrhoea (44; 45%), most of w

20 d with 10-300 lesions that were a mixture of acneiform, papular, nodular, and ulcerated types.

21 xed were fatigue (33 [11%] of 292 patients), acneiform rash (31 [11%]), dyspnoea (29 [10%]), and decr

22 2%] patients on dacomitinib vs no controls), acneiform rash (48 [10%] vs one [<1%]), oral mucositis (

23 vents were diarrhoea (83 patients, 64%), non-acneiform rash (77 patients, 60%), liver enzyme abnormal

24 The most common toxicities were acneiform rash (79%) and diarrhea (69%).

25 common treatment-related adverse events were acneiform rash (93%), diarrhea (89%), and proteinuria (7

26 s associated with bevacizumab-erlotinib were acneiform rash 1 (2%) and oral stomatitis 1 (2%) with er

27 With the exception of acneiform rash and infusion reactions, the incidence of

28 be useful in decreasing the severity of the acneiform rash during the first month of cetuximab treat

29 An acneiform rash occurred in 82.9% of patients; grade 3 ra

30 Mild to moderate (grade 1 to 2) acneiform rash occurred in a majority of patients; no gr

31 icantly improved in those who experienced an acneiform rash of at least grade 2 severity compared wit

32 (EGFR) antibody therapy often experience an acneiform rash of uncertain etiology in skin regions ric

33 The median (range) onset of acneiform rash was 45 (15-150) days.

34 ere similar to those of the pediatric trial; acneiform rash was the most prevalent AE.

35 treated with ELX-TEZ-IVA and referred for an acneiform rash were included.

36 both, to reduce or prevent cetuximab-related acneiform rash when administered starting on day 1 of ce

37 The most common toxicities were acneiform rash, diarrhea, hand reaction, dyspepsia, and

38 effects associated with selumetinib included acneiform rash, gastrointestinal effects, and asymptomat

39 The principal toxicity, an acneiform rash, occurred in 68%, 95%, 87%, and 100% of p

40 Onset of acneiform rash, type of lesions, and degree of severity,

41 ncrease in the creatine phosphokinase level; acneiform rash; and paronychia.

42 Six patients (37.5%) developed new-onset acneiform rashes, whereas 10 patients (62.5%) had a rela

43 the JCI, Satoh et al. define a mechanism for acneiform skin toxicity wherein EGFR/MEK inhibitors coop

44 commonly anaemia (two [13%]) and dermatitis acneiform (two [13%]).